XDx, Inc. has announced its participation at the 28th Annual JP Morgan Healthcare Conference on Wednesday, January 13. The presentation will take place at the Westin St. Francis Hotel in San Francisco, California. XDx President and Chief Executive Officer Pierre Cassigneul will address the conference at 3:30 pm PT that afternoon. The conference is expecting participation from over 300 public and private companies. Over 3,500 investors are anticipated to attend the event focused on healthcare industry leaders, fast growth companies, innovative technology creators, and globally minded service providers.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Rejection hurts, but organ transplant rejection hurts worse, and XDx wants to help. The company makes tests that monitor for cellular rejection in heart transplants. Its FDA-approved AlloMap test measures gene expression in patients' blood samples to determine if a transplanted heart has been accepted. The company believes its tests will help reduce costs by decreasing the number of biopsies and drug therapies often used in evaluating transplants in patients. XDx also has explored the development of AlloMap for lung transplant patients, and it has other molecular (gene-based) diagnostic research programs in areas such as immunology.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
